Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
[Paper-level Aggregated] PMCID: PMC3260002
Evidence Type(s): Oncogenic, Predictive, Prognostic
Justification: Oncogenic: The presence of DNMT3A exon 23 mutations, particularly at the R882 codon, is associated with acute myeloid leukemia (AML), indicating a role in tumorigenesis. Predictive: The identification of specific mutations in DNMT3A may help predict the response to certain treatments in AML patients, as these mutations are known to influence disease characteristics. Prognostic: The detection of DNMT3A mutations, especially at the R882 codon, can provide information about the likely course and outcome of the disease in AML patients.
Gene→Variant (gene-first): DNMT3A(1788):R882 DNMT3A(1788):R882C DNMT3A(1788):R882H DNMT3A(1788):R882P DNMT3A(1788):W893 DNMT3A(1788):W893S
Genes: DNMT3A(1788)
Variants: R882 R882C R882H R882P W893 W893S